EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC 4.0

Gene–Dose Interaction in Low‐Dose Irinotecan: A Real‐World Cohort Study of the Association Between Adverse Effects and UGT1A1 Polymorphism

Dafna Zukerman, Joul Hadad, Flavio Lejbkowicz, Ofra Barnett-Griness, Naomi Gronich iD

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2026-12 · 46 (12)

DOI: 10.1002/phar.70214 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, online erschienen am 09.11.2026. Verfasst von Dafna Zukerman und 4 weiteren Autor:innen. Beteiligte Einrichtung: Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel. Hauptthemen laut MEDLINE: Irinotecan, Glucuronosyltransferase, Polymorphism, Genetic, Antineoplastic Agents, Phytogenic. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Exposure to the toxic metabolite of irinotecan is higher in UGT1A1 poor metabolizers (PMs). It is uncertain if there is a higher risk for adverse effects in PMs receiving low‐dose irinotecan regimens (< 150 mg/m 2 ). In this retrospective cohort study, we examined in a real‐world cohort the interaction between UGT1A1 polymorphism and initial irinotecan dose, with severe adverse effects of irinotecan. Material and Methods We performed a retrospective cohort study based on Clalit Health Services (CHS) database, including all adults initiating irinotecan, with available UGT1A1 result. Short‐term outcomes, within 2 months of first irinotecan dose, were Grade 3 or 4 neutropenia, hospitalization, and mortality. A composite outcome included all of the above. Secondary outcomes were hospitalization due to diarrhea and long‐term overall survival. We used logistic regression models and a propensity score that included demographics, cancer‐related variables, chronic clinical conditions, and laboratory characteristics at cohort entry.

Result

Of 450 patients initiating irinotecan (2004–2025), 185 (41.1%) were UGT1A1 normal metabolizers (NMs), 211 (46.9%) were intermediate metabolizers (IMs), and 54 (12%) were PMs. Dosing data was available for 260 patients. UGT1A1 PM status was associated with increased risk for Grade‐3 neutropenia with an odds ratio (OR) of 4.36 (95% CI 1.29–14.82) in the higher dose group, with a median initial dose (interquartile range) of 107 (100–115) mg/m 2 . UGT1A1 PM status was not associated with increased toxicity risk in the lower dose group, with a median initial dose (interquartile range) of 80 (66–88) mg/m 2 . The risk for the composite outcome in PMs receiving the higher dose had an OR of 3.19 (95% CI 0.95–10.72) p = 0.06 (marginally significant). An interaction between UGT1A1 polymorphism and initial irinotecan dose was identified. Propensity‐score analysis and sensitivity analyses yielded similar results. There was no increased risk for hospitalizations due to diarrhea in PMs receiving higher doses of irinotecan, and no difference in overall survival was found between the four groups defined by polymorphism and initial dose.

Conclusion

Our data suggest a possible dose‐by‐genotype interaction within the irinotecan regimens of < 150 mg/m 2 . The findings may support heightened vigilance and motivate larger prospective studies to establish the recommended initial irinotecan dose with regard to the common UGT1A1 polymorphism.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IrinotecanGlucuronosyltransferasePolymorphism, GeneticAntineoplastic Agents, PhytogenicTopoisomerase I InhibitorsHumansUGT1A1 EnzymeRetrospective StudiesFemaleMiddle AgedMaleDose-Response Relationship, DrugCohort StudiesAgedNeutropeniaAdultHospitalization

Stichwörter der Autor:innen

UGT1A1adverse effectsirinotecanpharmacogeneticreal‐world

Substanzen

IrinotecanUGT1A1 EnzymeGlucuronosyltransferaseAntineoplastic Agents, PhytogenicTopoisomerase I Inhibitors

Autor:innen und Institutionen

  • Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
  • Lady Davis Carmel Medical Center, Clalit Health Services, Haifa, Israel.

ORCID-Profile: Naomi Gronich

Zitieren

APA

Zukerman, D., Hadad, J., Lejbkowicz, F., Barnett-Griness, O., & Gronich, N. (2026). Gene–Dose Interaction in Low‐Dose Irinotecan: A Real‐World Cohort Study of the Association Between Adverse Effects and UGT1A1 Polymorphism. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 46(12). https://doi.org/10.1002/phar.70214

Vancouver

Zukerman D, Hadad J, Lejbkowicz F, Barnett-Griness O, Gronich N. Gene–Dose Interaction in Low‐Dose Irinotecan: A Real‐World Cohort Study of the Association Between Adverse Effects and UGT1A1 Polymorphism. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2026;46(12). doi:10.1002/phar.70214

BibTeX
@article{Zukerman2026,
  author = {Zukerman, Dafna and Hadad, Joul and Lejbkowicz, Flavio and Barnett-Griness, Ofra and Gronich, Naomi},
  title = {Gene–Dose Interaction in Low‐Dose Irinotecan: A Real‐World Cohort Study of the Association Between Adverse Effects and UGT1A1 Polymorphism},
  journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year = {2026},
  volume = {46},
  number = {12},
  doi = {10.1002/phar.70214}
}
Kostenlos starten →